Sanofi share price: what's the latest after diluting Regeneron stake?
French drug maker Sanofi’s share price fell 3.3% after plans to exit US biotech firm Regeneron were made public.
French pharmaceutical group Sanofi announced on Tuesday 26 May 2020 that it has agreed to sell 11.8 million shares of US biotech firm Regeneron Pharmaceuticals' (NASDAQ: REGN) common stock through a registered offering at a price of US$515.00 per share.
Sanofi shares fell 3.3% following the announcement, while Regeneron saw its share price decline as much as 5.5% on an intra-day basis, based on IG trading data.
As at 10:00 CET on Wednesday 27 May 2020, Sanofi stocks are trading at 86.67 euros apiece.
IG is a world-leading online trading and investments provider for thousands of financial markets. With CFDs (read about CFDs here), you can buy long or sell short on Sanofi, Regeneron Pharmaceuticals and other healthcare stocks depending on whether you think prices will rise or fall. Start today by opening a live or demo IG account.
Share sale will result in US$12 billion pay-out for Sanofi
As part of the sale agreement, Regeneron will repurchase 9.8 million shares or US$5 billion in common stock from Sanofi at the offering price less the underwriting discount, as previously announced.
In connection with the offering, the underwriters have been granted an option to purchase up to 1.2 million additional Regeneron shares at the price payable by the underwriters in the offering, exercisable within the next 30 days.
If the option is fully exercised, the offering and repurchase will together result in gross proceeds to Sanofi of US$11.7 billion and the sale of Sanofi’s entire holding in Regeneron, excluding 400,000 Regeneron shares that Sanofi will continue to retain ‘in support of the ongoing collaboration with Regeneron’.
Sanofi currently holds approximately 23.2 million shares of Regeneron’s common stock, representing approximately 20.6% ownership.
According to the press release, Sanofi expects to use the net proceeds of the offering and the repurchase to further execute on its strategy to drive innovation and growth.
Paul Hudson, Chief Executive Officer, Sanofi, said that the decision to divest Sanofi’s holdings was ‘fully aligned’ and made in consultation with Regeneron. He added that the collaboration between both companies ‘has been one of the most productive in the industry’, not only in creating significant commercial value, but in the development of ‘important medicines for patients’.
Sanofi and Regeneron first collaborated in 2003, with Sanofi purchasing a shareholding in Regeneron a year later. The long-standing clinical and commercial collaboration has yielded five approved treatments to date with additional candidates currently in clinical development.
Gain access to Sanofi, Regeneron and thousands of equities via IG's world-leading trading and investments platform. With CFDs, you can buy long or sell short on a range of healthcare stocks depending on whether you think prices will rise or fall. Start today by opening a live or demo IG account.
Sanofi maintains 2020 earnings growth forecast at 5%
Sanofi will discontinue accounting for its ownership in Regeneron’s common shares under the equity method, following completion of the proposed public offering and share repurchase.
In lieu of this accounting change, Sanofi expects its earnings per share (EPS) to grow by approximately 5% in 2020 at a constant exchange rate, compared to 2019’s restated business EPS of €5.64. This is in line with Sanofi’s 2020 business EPS growth guidance.
The public offering is occurring simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs, together with Barclays, BNP Paribas, Citigroup, J.P. Morgan, Morgan Stanley as joint book-running managers.
How to trade healthcare stocks with IG
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Act on share opportunities today
Go long or short on thousands of international stocks with CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets